Replication conditional virus that specifically kills senescent cells

Patent metadata

Field	Value
Publication number	US-10378002-B2
Application number	US-201816029244-A
Country	US
Kind code	B2
Filing date	Jul 6, 2018
Priority date	Apr 17, 2012
Publication date	Aug 13, 2019
Grant date	Aug 13, 2019

Abstract

Polypeptides, viruses, methods and compositions provided herein are useful for the selective elimination of senescent cells. Method aspects include methods for inducing apoptosis in a senescent cell comprising administering to the cell a polynucleotide, virus, host cell, or pharmaceutical composition described herein. Other methods include expressing a pro-apoptotic gene in a senescent cell comprising administering to the cell the polynucleotide, virus, or pharmaceutical composition as described herein.

First claim

What is claimed is:

1. A senolytic virus, defined as a conditionally replicating virus having a recombinant genome construct in which a replication gene for the virus is placed under transcriptional control of one or more heterologous promoters,
wherein one of the heterologous promoters is the p16 promoter,
wherein when the senolytic virus is applied to a mixed cell population comprising senescent cells, the p16 promoter causes the virus to replicate preferentially in the senescent cells, thereby causing lysis of the senescent cells and selectively depleting them from the cell population.

2. The senolytic virus of claim 1 , wherein the genome construct comprises a replication gene for the virus placed under transcriptional control of a chemically inducible promoter.

3. The senolytic virus of claim 1 , which is an adenovirus.

4. The senolytic virus of claim 1 , which is a lentivirus, and the replication gene under transcriptional control of the p16 promoter is selected from gag, pol and env.

5. The senolytic virus of claim 1 , wherein the nucleotide sequence of the p16 promoter comprises SEQ. ID NO:1.

6. The senolytic virus of claim 1 , wherein the nucleotide sequence of the p16 promoter comprises SEQ. ID NO:2.

7. The senolytic virus of claim 1 , wherein the genome construct further comprises a caspase gene under transcriptional control of the p16 promoter.

8. A method of selectively depleting senescent cells from a mixed cell population or tissue, comprising combining the mixed population or tissue with a senolytic virus according to claim 1 .

Assignees

• Unity Biotechnology Inc
• Kythera Biopharmaceuticals Inc

Inventors

• Lichtsteiner Serge
• David Nathaniel

Classifications

• C12N9/503 Primary

  derived from viruses · CPC title

• C12N2740/15043

  viral genome or elements thereof as genetic vector · CPC title

• C12N15/85 Primary

  for animal cells · CPC title

• C12Y304/22

  Cysteine endopeptidases (3.4.22) · CPC title

• A61K38/4873

  Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H · CPC title